| Literature DB >> 35566312 |
Mthandazo Dube1, Dayma Llanes1, Mohamad Saoud1, Robert Rennert1, Peter Imming2, Cécile Häberli3,4, Jennifer Keiser3,4, Norbert Arnold1.
Abstract
Neglected tropical diseases affect the world's poorest populations with soil-transmitted helminthiasis and schistosomiasis being among the most prevalent ones. Mass drug administration is currently the most important control measure, but the use of the few available drugs is giving rise to increased resistance of the parasites to the drugs. Different approaches are needed to come up with new therapeutic agents against these helminths. Fungi are a source of secondary metabolites, but most fungi remain largely uninvestigated as anthelmintics. In this report, the anthelmintic activity of Albatrellus confluens against Caenorhabditis elegans was investigated using bio-assay guided isolation. Grifolin (1) and neogrifolin (2) were identified as responsible for the anthelmintic activity. Derivatives 4-6 were synthesized to investigate the effect of varying the prenyl chain length on anthelmintic activity. The isolated compounds 1 and 2 and synthetic derivatives 4-6, as well as their educts 7-10, were tested against Schistosoma mansoni (adult and newly transformed schistosomula), Strongyloides ratti, Heligmosomoides polygyrus, Necator americanus, and Ancylostoma ceylanicum. Prenyl-2-orcinol (4) and geranylgeranyl-2-orcinol (6) showed promising activity against newly transformed schistosomula. The compounds 1, 2, 4, 5, and 6 were also screened for antiproliferative or cytotoxic activity against two human cancer lines, viz. prostate adenocarcinoma cells (PC-3) and colorectal adenocarcinoma cells (HT-29). Compound 6 was determined to be the most effective against both cell lines with IC50 values of 16.1 µM in PC-3 prostate cells and 33.7 µM in HT-29 colorectal cells.Entities:
Keywords: Albatrellus confluens (Alb. & Schwein.) Kotl. & Pouz.; anthelmintic properties; anticancer activities; schistosomiasis
Mesh:
Substances:
Year: 2022 PMID: 35566312 PMCID: PMC9100200 DOI: 10.3390/molecules27092950
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1In vitro anthelmintic activity of crude extracts (500 µg/mL) of fungal fruiting bodies against C. elegans.
Figure 2Structures of the naturally occurring compounds 1 and 2.
Scheme 1Synthesis of compounds 1, 4–6 by regioselective alkylation of orcinol (3).
Figure 3The prenyl alcohols 7–10 used in the synthesis of the analogs.
In vitro anthelmintic activity of compounds 1–10 at 500 µg/mL in % mortality.
| Natural and Synthetic Compounds | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Anthelmintic activity against | 32.0 ± 4.8 | 100 ± 0 * | 0.7 ± 0.9 | 85.6 ± 5.1 * | 95.3 ± 2.8 * | 1.6 ± 2.3 |
|
|
|
|
|
|
|
|
| Anthelmintic activity against | 32.1 ± 3.0 | 32.1 ± 3.0 | - | 17.8 ± 1.7 | 99.5 ± 0.7 * | 0 |
* Compound activities determined to be significant versus control worms using Kruskal–Wallis non-parametric test (Statsdirect software version 3.2.8) with p < 0.05.
In vitro anthelmintic activity of compounds 1–6 against parasitic helminths.
| Activity % | ||||||
|---|---|---|---|---|---|---|
| Organism | 1 | 2 | 4 | 5 | 6 | Reference |
| NTS ** (10 µM) | 36.0 ± 4 | 26.0 ± 2 | 93.3 ± 0 *** | 55.0 ± 5.0 *** | 75.0 ± 5.0 *** | Auranofin 100 |
| NTS ** (1 µM) | nt | nt | 38.9 ± 1.7 | nt | 55.0 ± 1.7 *** | nt |
| 27.3 ± 2 | 35.1 ± 2 | 29.2 ± 4.2 | 0 | 16.7 ± 0 | Praziquantel 100 | |
| 16.5 ± 12.5 | 13.4 ± 8.4 | 12.1 ± 8.9 | 29.6 ± 2.4 | 28.2 ± 7.4 | Levamisole 100 | |
| 18.6 ± 7.8 | 18 ± 2 | 1.9 ± 13.1 | 2.9 ± 5.6 | 0 | Levamisole 100 | |
| 16.4 ± 0.4 | 16 ± 4.3 | 23.4 ± 7.3 | 38.6 ± 4.8 | 36.6 ± 1.9 | Levamisole 100 | |
| 2.0 ± 2.5 | 7.5 ± 0 | 24.4 ± 7.8 | 19 ± 14.1 | 17.5 ± 3.9 | Abamectin 100 | |
* Mortality % based on three replicates; ** NTS = newly transformed schistosomula; nt = not tested. *** compound activities determined to be significant versus control worms using Kruskal–Wallis non-parametric test (Statsdirect software version 3.2.8) with p < 0.05.
In vitro anthelmintic activity of prenyl alcohols 7–10 against parasitic helminths.
| Activity % * | |||||
|---|---|---|---|---|---|
| Organism | 7 | 8 | 9 | 10 | Reference |
| NTS ** (10 µM) | 33.3 ± 0 | 31.3 ± 2 | 25 ± 0 | 31.3 ± 2 | Auranofin 100 |
| nt | nt | nt | nt | nt | |
| 11.6 ± 2 | 11.3 ± 10 | 21.3 ± 1 | 36.3 ± 1 | Levamisole 100 | |
| 13 ± 5 | 39.6 ± 0.4 | 0.2 ± 9 | 0 | Levamisole 100 | |
| 0 | 1.8 ± 5 | 34.6 ± 5.5 | 0 | Levamisole 100 | |
| 18.8 ± 2.9 | 13.7 ± 1.7 | 10 ± 6.4 | 23.6 ± 5.9 | Abamectin 100 | |
* Mortality % based on three replicates; ** NTS = newly transformed schistosomula; nt = not tested.
Figure 4Effect of the compounds 1, 2, 4, 5, and 6 on the metabolic cell viability of (A) prostate PC-3 and (B) colorectal HT-29 cancer cells, respectively, as determined by MTT assay (left), and general cytotoxic and antiproliferative effect as determined by using crystal violet (CV) assay (right) after 48 h cell treatment. Data represent biological triplicates, each comprising technical quadruplicates. IC50 curves were analyzed and drawn using GraphPad Prism software. IC50 values are given with its calculated 95% confidence intervals (95% CI); n.d.: mathematically not definable based on the available data.